M. Hutmacher

发表

Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.

Kaori Ito, M. Hutmacher, 2014, Journal of Alzheimer's disease : JAD.

Modeling the Exposure‐Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis

I. Nestorov, M. Hutmacher, R. Zitnik, 2007, Journal of clinical pharmacology.

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

M. Hutmacher, T. Machnig, T. Craig, 2018, CPT: pharmacometrics & systems pharmacology.

Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test

M. Hutmacher, K. Kowalski, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Covariate selection in pharmacometric analyses: a review of methods

M. Hutmacher, K. Kowalski, 2015, British journal of clinical pharmacology.

Dosing Celecoxib in Pediatric Patients With Juvenile Rheumatoid Arthritis

M. Hutmacher, A. Bello, S. Krishnaswami, 2012, Journal of clinical pharmacology.

A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

M. Hutmacher, J. Nielsen, Bei Yang, 2018, Cancer Chemotherapy and Pharmacology.

Population dose‐response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures

M. Hutmacher, K. Kowalski, D. Tolbert, 2015, Journal of clinical pharmacology.

Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

S. Preskorn, M. Hutmacher, R. Lalonde, 2009, Journal of clinical pharmacology.

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials

J. Isaacs, M. Hutmacher, K. Kowalski, 2014, Arthritis Research & Therapy.

Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease

Steven W. Martin, M. Hutmacher, A. Cleton, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Use of statistical and pharmacokinetic–pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference

M. Hutmacher, V. Sethuraman, N. Mehrotra, 2017, Journal of biopharmaceutical statistics.

Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites

M. Hutmacher, J. Stone, M. Stroh, 2013, The AAPS Journal.

Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

B. Corrigan, M. Hutmacher, K. Ito, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Application of a hazard-based visual predictive check to evaluate parametric hazard models

M. Hutmacher, Y. Huh, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Correction: Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach

J. Goñi, N. Vélez de Mendizábal, P. Villoslada, 2014, PLoS ONE.

Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach

Joaquín Goñi, Pablo Villoslada, Iñaki F. Troconiz, 2013, PloS one.

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

A. Hui, K. Venkatakrishnan, M. Hutmacher, 2015, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Pegaptanib in Patients With Neovascular, Age‐Related Macular Degeneration

M. Hutmacher, K. Kowalski, L. Whitfield, 2012, Journal of clinical pharmacology.

Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients

M. Hutmacher, K. Kowalski, S. Krishnaswami, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder

Matthew M. Hutmacher, Bill Frame, Raymond Miller, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

M. Hutmacher, J. Nielsen, Bei Yang, 2018, Cancer Chemotherapy and Pharmacology.

The pharmacokinetics of etanercept in patients with end‐stage renal disease on haemodialysis

I. Nestorov, M. Hutmacher, G. Kaysen, 2005, The Journal of pharmacy and pharmacology.

Estimating transformations for repeated measures modeling of continuous bounded outcome data

J. French, M. Hutmacher, S. Krishnaswami, 2011, Statistics in medicine.

Performance Characteristics for Some Typical QT Study Designs Under the ICH E‐14 Guidance

M. Hutmacher, M. Agin, R. Lalonde, 2008, Journal of clinical pharmacology.

Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites

M. Hutmacher, J. Stone, M. Stroh, 2013, The AAPS Journal.

Modeling Dropout From Adverse Event Data: Impact of Dosing Regimens Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder

Raymond Miller, M. Hutmacher, B. Frame, 2011, Journal of clinical pharmacology.

Evaluation of Random Sparse Sampling Designs for a Population Pharmacokinetic Study: Assessment of Power and Bias Using Simulation

Kenneth G. Kowalski, Matthew M. Hutmacher, M. Hutmacher, 2002 .

Translational PK–PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576

R. Bursi, M. Hutmacher, J. Schipper, 2011, Psychopharmacology.

An alternative method for population pharmacokinetic data analysis under noncompliance

Raymond Miller, Pankaj Gupta, Matthew M. Hutmacher, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study.

K G Kowalski, M. Hutmacher, K. Kowalski, 2001, Statistics in medicine.

Comparison of QTc Data Analysis Methods Recommended by the ICH E14 Guidance and Exposure–Response Analysis: Case Study of a Thorough QT Study of Asenapine

M. Hutmacher, R. Lalonde, S. Chapel, 2011, Clinical pharmacology and therapy.

Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema

M. Hutmacher, K. Kowalski, A. Basile, 2015, Clinical ophthalmology.

A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data

Lynn McFadyen, Kenneth G. Kowalski, Matthew M. Hutmacher, 2003, Journal of Pharmacokinetics and Pharmacodynamics.

Model‐based Drug Development

W Ewy, B. Corrigan, Raymond Miller, 2007, Clinical pharmacology and therapeutics.

Extending the latent variable model for extra correlated longitudinal dichotomous responses

Matthew M. Hutmacher, J. French, M. Hutmacher, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease

Steven W. Martin, M. Hutmacher, A. Cleton, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema

M. Hutmacher, K. Kowalski, A. Basile, 2015, Clinical ophthalmology.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

M. Hutmacher, K. Liao, B. Gumbiner, 2016, British journal of clinical pharmacology.

Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

B. Corrigan, M. Hutmacher, M. Hutmacher, 2012, Journal of Pharmacokinetics and Pharmacodynamics.